Cagrilintide: the amylin analog behind CagriSema, on its own terms

Most of the attention in obesity pharmacology has fixed on one hormone pathway — GLP-1. Cagrilintide is the molecule that quietly makes the case for a different one. It is a long-acting analog of amylin, a gut-brain hormone with its own appetite-suppressing job, engineered by Novo Nordisk to be dosed once weekly. It is best known as one half of the combination CagriSema, but it has a standalone evidence base worth reading on its own terms — and understanding cagrilintide alone is the cleanest way to see what amylin agonism actually contributes.

Amylin is not GLP-1 — and that is the point

Amylin is a peptide hormone co-secreted with insulin from pancreatic β-cells after a meal. Its physiology is distinct from the incretin system: rather than amplifying insulin release the way GLP-1 does, amylin acts chiefly as a satiation signal — it slows gastric emptying, blunts the post-meal rise in glucagon, and signals fullness through receptors in the hindbrain.^[1] In other words, amylin and GLP-1 both reduce how much you eat, but they get there through largely separate machinery. That separation is the entire pharmacological argument for developing an amylin drug at all. If a second, independent appetite brake exists, it can in principle be pulled on its own or stacked on top of GLP-1 — which is precisely the logic the field has pursued.

Why an analog, and why long-acting

Native human amylin is a poor drug. It aggregates, is unstable, and clears quickly, which is why the first clinical amylin agonist, pramlintide, had to be dosed multiple times a day at mealtimes. Cagrilintide was designed to fix that: it is a structurally modified, soluble amylin analog with a fatty-acid modification that extends its half-life enough for once-weekly subcutaneous dosing, matching the cadence of modern GLP-1 therapies.^[2] This re-engineering is what turned amylin from a niche, inconvenient adjunct into a candidate weight-management agent in its own right. The development of long-acting amylin analogs like cagrilintide is, fairly read, the event that revived serious interest in the amylin pathway for obesity.^[2]

The monotherapy data: cagrilintide on its own

The pivotal standalone evidence is a multicentre, randomised, double-blind, placebo- and active-controlled Phase 2 dose-finding trial of once-weekly cagrilintide in adults with overweight or obesity but without type 2 diabetes.^[3] Over 26 weeks, cagrilintide produced dose-dependent weight loss that meaningfully exceeded placebo, with the higher doses delivering placebo-subtracted reductions in the mid-single-digit to roughly 10 percent range — and notably, the top cagrilintide doses also outperformed the liraglutide active comparator in that trial.^[3] That is the headline that matters: amylin agonism alone, without any GLP-1 on board, is a genuine weight-management lever, not merely a helper molecule. The trial was a dose-finding study rather than a long, hard-outcome Phase 3, so the honest framing is proof-of-concept-grade efficacy — convincing for the mechanism, not yet a settled clinical verdict.

How it differs from the GLP-1 drugs people know

Three differences are worth keeping straight. First, target: cagrilintide acts on amylin (calcitonin-receptor/RAMP) signalling, not the GLP-1 receptor, so it is mechanistically a different class even though the clinical goal overlaps.^[1] Second, effect size and maturity: the most potent GLP-1 and dual GLP-1/GIP agonists currently carry larger and far more extensively documented weight-loss and outcome data than cagrilintide monotherapy, whose standalone record is still mainly Phase 2. Third, tolerability character: amylin agonists share the gastrointestinal, dose-dependent side-effect tendency of the broader gut-hormone class, with nausea the common limiter as the dose escalates. The practical upshot is that cagrilintide is not a stronger or weaker version of a GLP-1 — it is a complementary tool that happens to chase the same outcome by a different route.

The “other half” of CagriSema

Cagrilintide’s highest-profile role is as the amylin component of CagriSema, the fixed-dose combination that pairs it with the GLP-1 agonist semaglutide in a single weekly injection. The rationale follows directly from the mechanism above: if amylin and GLP-1 suppress appetite through complementary pathways, combining them could add up to more than either alone. That hypothesis was supported early by a Phase 1b study showing the two peptides could be co-administered with a pharmacokinetic and tolerability profile compatible with a fixed-dose combination,^[4] and it was then carried into the large REDEFINE Phase 3 program. We cover that combination, and the more nuanced-than-hyped results it produced, in our companion piece on CagriSema and the REDEFINE program. The key point for this page is the order of the logic: cagrilintide had to stand up as a credible weight-loss agent on its own first, which the Phase 2 monotherapy data did, before it earned its place as the amylin half of the combination.

Where it sits in the pipeline

Cagrilintide occupies an unusual position. As a standalone agent it is, at the time of writing, still defined principally by Phase 2 monotherapy evidence rather than a completed standalone Phase 3 obesity program — so it is best described as an investigational amylin analog with strong proof-of-concept efficacy, not an established stand-alone therapy. Its near-term clinical relevance has run mostly through the combination route, where its regulatory fate is tied to the larger CagriSema dataset and to decisions that belong to regulators reviewing the full evidence, not to a press cycle. More broadly, cagrilintide is the clearest current example of a wider trend: obesity drug development is expanding beyond GLP-1 monotherapy toward multi-hormone strategies, and the amylin pathway is one of the most credible additional levers in that expansion.^[2]

The honest bottom line

Cagrilintide matters because it validates a second appetite pathway. It is a re-engineered, long-acting amylin analog that, dosed once weekly and entirely on its own, produced dose-dependent weight loss in a controlled Phase 2 trial and even beat a GLP-1 comparator at its higher doses.^[3] That makes it a legitimate weight-management mechanism in its own right, not merely semaglutide’s sidekick. The fair caveats are that its standalone evidence is still proof-of-concept-grade rather than a mature outcomes program, that it carries the gut-hormone class’s gastrointestinal tolerability profile, and that most of its public story has been written as the amylin half of CagriSema. Read cleanly, cagrilintide is a promising, mechanistically distinct amylin analog — convincing on biology, still early on the standalone clinical record.